FDA Accepts Supplement for XELSTRYM by Noven Pharmaceuticals
The FDA has accepted a supplemental application for XELSTRYM, an ADHD treatment containing dextroamphetamine.
Company
Pharmaceutical intelligence for Noven Pharmaceuticals with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.